Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REPL Replimune Group Inc.

Pre-Mkt 08-19 09:24:51 EDT

15.58

+0.95

+6.49%

盘前15.18

-0.40-2.57%

09:20 EDT

High15.62	Low14.50	Vol2.25M
Open14.60	D1 Closing14.63	Amplitude7.62%
Mkt Cap1.47B	Tradable Cap1.21B	Total Shares94.22M
T/O34.50M	T/O Rate2.90%	Tradable Shares77.49M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"REPL","market":"US","secType":"STK","nameCN":"Replimune Group Inc.","latestPrice":15.58,"timestamp":1787083200000,"preClose":14.63,"halted":0,"volume":2245162,"hourTrading":{"tag":"盘前","latestPrice":15.18,"preClose":15.58,"latestTime":"09:20 EDT","volume":45581,"amount":685141.138328,"timestamp":1787145647161,"change":-0.4,"changeRate":-0.025674,"amplitude":0.051348},"delay":0,"changeRate":0.06493506493506489,"floatShares":77485633,"shares":94219634,"eps":-3.154987,"marketStatus":"Pre-Mkt","change":0.95,"latestTime":"08-19 09:24:51 EDT","open":14.6,"high":15.615,"low":14.5,"amount":34496934.336458005,"amplitude":0.076213,"askPrice":15.2,"askSize":109,"bidPrice":15.1,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-3.154987,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787146200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1532059200000,"exchange":"NASDAQ","adjPreClose":15.58,"preHourTrading":{"tag":"盘前","latestPrice":15.18,"preClose":15.58,"latestTime":"09:20 EDT","volume":45581,"amount":685141.138328,"timestamp":1787145647161,"change":-0.4,"changeRate":-0.025674,"amplitude":0.051348},"postHourTrading":{"tag":"盘后","latestPrice":15.54,"preClose":15.58,"latestTime":"19:52 EDT","volume":24101,"amount":375427.9824,"timestamp":1787097161323,"change":-0.04,"changeRate":-0.002567,"amplitude":0.009615},"volumeRatio":0.5012834833707432,"impliedVol":0.7738,"impliedVolPercentile":0.092},"requestUrl":"/m/hq/s/REPL/wiki","defaultTab":"wiki","newsList":[{"id":"2660413569","title":"Trump Picks White House Adviser Heidi Overton to Run FDA, Source Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2660413569","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660413569?lang=en_us&edition=fundamental","pubTime":"2026-08-19 08:35","pubTimestamp":1787099724,"startTime":"0","endTime":"0","summary":"UPDATE 3-Trump picks White House adviser Heidi Overton to run FDA, source saysAug 18 (Reuters)-U.S. President Donald Trump has chosen White House policy aide Heidi Overton to lead the Food and Drug Ad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nL6N44G00Q:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX","MRNA","BK4139","MRNY","BK4532","IE0002141913.USD","IE00B2B36J28.USD","LGHT","BK4534","REPL","IE00BFTCPJ56.SGD","BK4568","IE00BJJMRZ35.SGD","BK4548","IDNA","BK4585","BK4563","BK4588","BK4551","WDNA","BK4501","BK4533","SRPU","IE0009355771.USD","MRNX","BK4505","SRPT","GNOM","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660494146","title":"Replimune Group Lawsuit Focuses on FDA Disclosure Issues and Sharp REPL Stock Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2660494146","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660494146?lang=en_us&edition=fundamental","pubTime":"2026-08-19 03:29","pubTimestamp":1787081359,"startTime":"0","endTime":"0","summary":"Replimune Group, Inc. (NASDAQ: REPL) is facing a federal securities lawsuit alleging that investors were not told key facts about regulatory weakne...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/replimune-group-lawsuit-focuses-on-fda-disclosure-issues-and-sharp-repl-stock-drop?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/replimune-group-lawsuit-focuses-on-fda-disclosure-issues-and-sharp-repl-stock-drop?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QQQE","NVIW.SI","NQmain","QQQY","TECS","QYLG","SQQQ","PSQ","BK4139","BK4585","BK4588","MNQmain","FTEC","QQQA","QQQJ","ONEQ","LABU","JEPQ","NDX","QQQM","QQQ","TQQQ","GPIQ","QDTE","QID",".IXIC","TQQY","QLD","REPL","IYW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660436614","title":"Jefferies Remains a Buy on Replimune Group (REPL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660436614","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660436614?lang=en_us&edition=fundamental","pubTime":"2026-08-17 23:15","pubTimestamp":1786979742,"startTime":"0","endTime":"0","summary":"In a report released today, Roger Song from Jefferies maintained a Buy rating on Replimune Group, with a price target of $24.00. Song covers the He...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-remains-a-buy-on-replimune-group-repl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-remains-a-buy-on-replimune-group-repl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659172475","title":"Replimune files automatic mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2659172475","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659172475?lang=en_us&edition=fundamental","pubTime":"2026-08-16 20:38","pubTimestamp":1786883912,"startTime":"0","endTime":"0","summary":"16:53 EDT Replimune (REPL) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving brea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-files-automatic-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-files-automatic-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659121931","title":"Replimune Group, Inc. Files for Mixed Shelf; Size not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2659121931","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659121931?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:53","pubTimestamp":1786740803,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nFWN44B2BE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659126569","title":"Replimune Group Lawsuit Alleges Investors Were Misled Before REPL Stock Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2659126569","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659126569?lang=en_us&edition=fundamental","pubTime":"2026-08-15 03:16","pubTimestamp":1786734977,"startTime":"0","endTime":"0","summary":"Replimune Group, Inc. (NASDAQ: REPL) is facing a federal securities lawsuit alleging that the company misled investors about the regulatory strengt...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/replimune-group-lawsuit-alleges-investors-were-misled-before-repl-stock-drop?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/replimune-group-lawsuit-alleges-investors-were-misled-before-repl-stock-drop?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","GPIQ","QLD","QQQM","QQQJ","QYLG","BK4139","QQQY","QQQE","TQQY","QDTE","ONEQ","NDX","PSQ","QQQ","SQQQ","NQmain","REPL",".IXIC","TECS","TQQQ","MNQmain","JEPQ","ISBC","NVIW.SI","QQQA","IYW","FTEC","QID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659415291","title":"Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659415291","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659415291?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:40","pubTimestamp":1786711203,"startTime":"0","endTime":"0","summary":"BRIEF-Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate UpdateAug 14 (Reuters)-Replimune Group, Inc.REPL.O:REPLIMUNE REPORTS FISCAL FIRST QUARTER 2027 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATESource text:ID:nGNX4b8z5dFurther company coverage:REPL.O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUABPJTYV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659149626","title":"Replimune Q1 Net Loss Narrows as Expenses Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2659149626","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659149626?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:14","pubTimestamp":1786709664,"startTime":"0","endTime":"0","summary":"Replimune Q1 net loss narrows as expenses declineOverviewUS oncolytic immunotherapy firm's fiscal Q1 net loss narrowed year-over-yearCompany received FDA accelerated approval for TUDRIQEV in advanced ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0EB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","IMNM","CRDF","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659304149","title":"Earnings Flash (REPL) Replimune Posts Fiscal Q1 Net Loss $0.72 a Share, vs. FactSet Est of $0.66 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2659304149","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659304149?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:09","pubTimestamp":1786709343,"startTime":"0","endTime":"0","summary":"Earnings Flash (REPL) Replimune Posts Fiscal Q1 Net Loss $0.72 a Share, vs. FactSet Est of $0.66 Loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659149316","title":"Replimune Group Q1 EPS $(0.72) Beats $(0.73) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659149316","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659149316?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:06","pubTimestamp":1786709186,"startTime":"0","endTime":"0","summary":"Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.73) by 1.37 percent. This is a 24.21 percent increase over losses of $(0.95) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61205474/replimune-group-q1-eps-0-72-beats-0-73-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659146057","title":"Replimune FY27 Q1 Net Loss Narrows to $69.8 Million; R&D Expenses Fall to $49.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659146057","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659146057?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:02","pubTimestamp":1786708955,"startTime":"0","endTime":"0","summary":"Replimune FY27 Q1 net loss narrows to $69.8 million; R&D expenses fall to $49.3 millionReplimune posted a GAAP net loss of USD 69.8 million for fiscal Q1 ended June 30, 2026, narrowing from USD 86.7 m","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL8DSTHr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","SG9999014013.SGD","BCDF","NDAQ","LU0314104364.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU2210149790.SGD","REPL","IE00BGHQF748.EUR","SG9999014039.USD","IE00BN0W2T93.GBP","LU2095319765.USD","LU2210150020.SGD","IE00BN0W2W23.USD","BK4112","IE00BN0W2V16.EUR","SG9999014005.SGD","BK4585","BK4588","BK4139","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659467691","title":"Replimune Group Q1 EPS USD -0.72","url":"https://stock-news.laohu8.com/highlight/detail?id=2659467691","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659467691?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:01","pubTimestamp":1786708911,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nPLX9PV7WM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658946012","title":"Baker Bros. Advisors Membeli Saham Replimune Senilai USD 33,01 Juta","url":"https://stock-news.laohu8.com/highlight/detail?id=2658946012","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658946012?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:47","pubTimestamp":1786484824,"startTime":"0","endTime":"0","summary":"Baker Bros. Advisors membeli saham Replimune senilai USD 33,01 jutaBaker Bros. Advisors membeli 2026 $0.0001 Prefunded Warrants Replimune Group, Inc. sebanyak 2.736.340 unit pada harga USD 12,06 per w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL88RMNL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Baker Bros. Advisors Membeli Saham Replimune Senilai USD 33,01 Juta","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658994189","title":"Replimune Amends Filing to Correct Pre-Funded Warrant Beneficial Ownership Limits","url":"https://stock-news.laohu8.com/highlight/detail?id=2658994189","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658994189?lang=en_us&edition=fundamental","pubTime":"2026-08-11 18:03","pubTimestamp":1786442597,"startTime":"0","endTime":"0","summary":"Replimune amends filing to correct pre-funded warrant beneficial ownership limitsReplimune filed an amended 8-K to correct the beneficial ownership limits tied to its pre-funded warrants from an Aug. 10 filing.Warrant exercise is capped at 4.99% beneficial ownership, with an investor option to reset up to 19.99% with 61 days’ notice.The correction relates to a $12.06-per-share equity offering of 9,701,490 shares, with 2,736,340 pre-funded warrants priced at $12.06 each.Estimated net proceeds remain about $140.5 million, with closing expected around Aug. 11.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL103Vy7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658995319","title":"Replimune Shares Rise After Pricing of Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2658995319","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658995319?lang=en_us&edition=fundamental","pubTime":"2026-08-11 01:45","pubTimestamp":1786383900,"startTime":"0","endTime":"0","summary":"Shares of Replimune Group rose after the biotechnology company said its underwritten offering of 9.7 million shares was priced at $12.06 a share.The stock was up 15% to $13.81 in recent trading, and has risen 42% since the start of the year.Proceeds from the offering are expected to be approximately $150 million.The offering is expected to close Aug. 11.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658533529","title":"Replimune Jumps After $150 Mln Equity Offering for Skin Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2658533529","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658533529?lang=en_us&edition=fundamental","pubTime":"2026-08-11 01:25","pubTimestamp":1786382747,"startTime":"0","endTime":"0","summary":"BUZZ-Replimune jumps after $150 mln equity offering for skin cancer drug** Replimune'sREPL.Oshares jump 14.5% to $13.82 on Mon after $150 mln follow-on priced to fund its recently-approved skin cancer","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL6N4470UP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","LU1718418525.SGD","LU0306807586.USD","LU1868836757.USD","IE0002141913.USD","LU0456855351.SGD","IHE","LU1868836591.USD","BK4007","FTXH","LU2242652126.USD","LU0225771236.USD","LU1571399168.USD","LU2125154778.USD","LU0061475181.USD","BK4534","LU0225284248.USD","LU1074936037.SGD","LU0321505439.SGD","IE00B2B36J28.USD","LU1291159041.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU1868836914.USD","LU0237698245.USD","LU1323610961.USD","LU1430594728.SGD","BK4585","LU0882574055.USD","LU0985481810.HKD","BK4559","LU0096364046.USD","LU2360032135.SGD","LU1670710661.SGD","REPL","LU1670710588.SGD","LU2133065610.SGD","IE00BJT1NW94.SGD","IE00BFXG1179.USD","LU1983299246.USD","LU2125154935.USD","LU1868837300.USD","LU0114720955.EUR","LU0868494617.USD","BK4139","BMY","LU1032466523.USD","LU1261432733.SGD","BK4581","LU1989771016.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658593518","title":"Replimune Group, - Prices Offering of 9.7 Mln Shares at $12.06 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2658593518","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658593518?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:00","pubTimestamp":1786363202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUA7SVYQV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658183935","title":"Replimune Group, - Offers 2.7 Mln Pre-Funded Warrants at $12.06 Per Warrant","url":"https://stock-news.laohu8.com/highlight/detail?id=2658183935","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658183935?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:00","pubTimestamp":1786363202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUA7SVYQV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658935584","title":"Replimune Prices USD 150 Million Follow-on Stock Offering at USD 12.06 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2658935584","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658935584?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:53","pubTimestamp":1786362787,"startTime":"0","endTime":"0","summary":"Replimune prices USD 150 million follow-on stock offering at USD 12.06 per shareReplimune priced an underwritten follow-on offering expected to raise about USD 150 million in gross proceeds.Deal inclu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL77l6NF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNSH","BK4207","BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657221640","title":"Replimune Group Price Target Raised to $20.00/Share from $17.00 by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2657221640","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657221640?lang=en_us&edition=fundamental","pubTime":"2026-08-08 00:51","pubTimestamp":1786121460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/REPL/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.replimune.com;ir.replimune.com","stockEarnings":[{"period":"1week","weight":0.1414},{"period":"1month","weight":0.523},{"period":"3month","weight":2.0194},{"period":"6month","weight":0.8222},{"period":"1year","weight":1.9231},{"period":"ytd","weight":0.6029}],"compareEarnings":[{"period":"1week","weight":-0.004},{"period":"1month","weight":0.0325},{"period":"3month","weight":0.0353},{"period":"6month","weight":0.1212},{"period":"1year","weight":0.193},{"period":"ytd","weight":0.1254}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":-0.013766},{"month":2,"riseRate":0.375,"avgChangeRate":-0.050762},{"month":3,"riseRate":0.25,"avgChangeRate":-0.088086},{"month":4,"riseRate":0.5,"avgChangeRate":0.020849},{"month":5,"riseRate":0.5,"avgChangeRate":0.255044},{"month":6,"riseRate":0.875,"avgChangeRate":0.229422},{"month":7,"riseRate":0.375,"avgChangeRate":-0.075914},{"month":8,"riseRate":0.444444,"avgChangeRate":0.064327},{"month":9,"riseRate":0.25,"avgChangeRate":-0.055352},{"month":10,"riseRate":0.625,"avgChangeRate":0.268092},{"month":11,"riseRate":0.625,"avgChangeRate":0.036282},{"month":12,"riseRate":0.25,"avgChangeRate":-0.087028}],"exchange":"NASDAQ","name":"Replimune Group Inc.","nameEN":"Replimune Group Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Replimune Group Inc.(REPL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Replimune Group Inc.,REPL,Replimune Group Inc.股票,Replimune Group Inc.股票老虎,Replimune Group Inc.股票老虎国际,Replimune Group Inc.行情,Replimune Group Inc.股票行情,Replimune Group Inc.股价,Replimune Group Inc.股市,Replimune Group Inc.股票价格,Replimune Group Inc.股票交易,Replimune Group Inc.股票购买,Replimune Group Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Replimune Group Inc.(REPL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}